Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arrhythmogenic Right Ventricular Dysplasia | 62 | 2022 | 75 | 10.330 |
Why?
|
Cardiomyopathies | 33 | 2022 | 167 | 6.780 |
Why?
|
Amyloid Neuropathies, Familial | 18 | 2022 | 21 | 5.760 |
Why?
|
Cardiomyopathy, Dilated | 16 | 2023 | 106 | 5.370 |
Why?
|
Mutation | 44 | 2021 | 1213 | 4.390 |
Why?
|
Prealbumin | 16 | 2022 | 25 | 3.440 |
Why?
|
Genetic Predisposition to Disease | 35 | 2021 | 786 | 3.270 |
Why?
|
Genetic Testing | 21 | 2021 | 159 | 2.900 |
Why?
|
Heart Failure | 25 | 2022 | 1179 | 2.310 |
Why?
|
Plakophilins | 16 | 2020 | 19 | 2.250 |
Why?
|
Phenotype | 36 | 2021 | 946 | 2.080 |
Why?
|
Marfan Syndrome | 14 | 2015 | 42 | 1.770 |
Why?
|
Death, Sudden, Cardiac | 14 | 2022 | 141 | 1.760 |
Why?
|
Amyloid | 6 | 2017 | 39 | 1.540 |
Why?
|
Humans | 162 | 2023 | 68549 | 1.390 |
Why?
|
Desmosomes | 7 | 2019 | 14 | 1.370 |
Why?
|
Amyloidosis | 8 | 2020 | 48 | 1.340 |
Why?
|
Arrhythmias, Cardiac | 13 | 2022 | 239 | 1.280 |
Why?
|
Myocardium | 18 | 2022 | 1204 | 1.280 |
Why?
|
Muscular Dystrophy, Duchenne | 6 | 2018 | 20 | 1.120 |
Why?
|
Indazoles | 2 | 2022 | 12 | 1.070 |
Why?
|
Mitral Valve | 6 | 2017 | 166 | 1.070 |
Why?
|
Middle Aged | 74 | 2023 | 21119 | 1.050 |
Why?
|
Female | 103 | 2023 | 38021 | 1.040 |
Why?
|
Cardiomyopathy, Hypertrophic, Familial | 5 | 2012 | 8 | 1.020 |
Why?
|
Male | 99 | 2023 | 37283 | 1.000 |
Why?
|
Myocytes, Cardiac | 8 | 2021 | 442 | 0.980 |
Why?
|
Pedigree | 19 | 2021 | 159 | 0.970 |
Why?
|
Cardiomyopathy, Hypertrophic | 3 | 2016 | 116 | 0.950 |
Why?
|
Electrocardiography | 20 | 2020 | 601 | 0.940 |
Why?
|
Benzoxazoles | 7 | 2021 | 12 | 0.930 |
Why?
|
Heterozygote | 10 | 2018 | 174 | 0.910 |
Why?
|
Adult | 71 | 2022 | 21379 | 0.910 |
Why?
|
Ethylenediamines | 1 | 2022 | 5 | 0.860 |
Why?
|
Isolated Noncompaction of the Ventricular Myocardium | 1 | 2022 | 5 | 0.850 |
Why?
|
Tachycardia, Ventricular | 9 | 2022 | 153 | 0.850 |
Why?
|
Mutation, Missense | 5 | 2017 | 112 | 0.850 |
Why?
|
Heart Valve Diseases | 3 | 2011 | 123 | 0.830 |
Why?
|
Defibrillators, Implantable | 13 | 2022 | 329 | 0.810 |
Why?
|
Peripartum Period | 2 | 2021 | 15 | 0.790 |
Why?
|
Microfilament Proteins | 10 | 2013 | 102 | 0.790 |
Why?
|
Exome | 2 | 2018 | 20 | 0.780 |
Why?
|
Connectin | 1 | 2020 | 14 | 0.750 |
Why?
|
Mitral Valve Insufficiency | 4 | 2017 | 99 | 0.740 |
Why?
|
RNAi Therapeutics | 1 | 2020 | 3 | 0.740 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2017 | 34 | 0.730 |
Why?
|
Sarcomeres | 4 | 2018 | 32 | 0.720 |
Why?
|
Physical Conditioning, Animal | 2 | 2021 | 34 | 0.690 |
Why?
|
Genetic Counseling | 5 | 2018 | 45 | 0.680 |
Why?
|
DNA Mutational Analysis | 12 | 2017 | 159 | 0.680 |
Why?
|
Risk Assessment | 16 | 2020 | 2004 | 0.670 |
Why?
|
Benzoates | 1 | 2019 | 20 | 0.670 |
Why?
|
Endocardium | 3 | 2016 | 101 | 0.660 |
Why?
|
Medical History Taking | 2 | 2019 | 94 | 0.660 |
Why?
|
Family Health | 4 | 2022 | 83 | 0.640 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 434 | 0.630 |
Why?
|
Calcium Channel Blockers | 3 | 2015 | 137 | 0.620 |
Why?
|
NAV1.5 Voltage-Gated Sodium Channel | 2 | 2017 | 6 | 0.610 |
Why?
|
Pyrazoles | 1 | 2019 | 190 | 0.610 |
Why?
|
Prognosis | 15 | 2022 | 2093 | 0.610 |
Why?
|
Lamin Type A | 4 | 2022 | 9 | 0.600 |
Why?
|
Young Adult | 28 | 2021 | 5710 | 0.590 |
Why?
|
Cell Differentiation | 4 | 2019 | 1034 | 0.590 |
Why?
|
alpha-Galactosidase | 1 | 2016 | 3 | 0.580 |
Why?
|
Fabry Disease | 1 | 2016 | 6 | 0.580 |
Why?
|
Endomyocardial Fibrosis | 1 | 2016 | 5 | 0.580 |
Why?
|
Risk Factors | 22 | 2022 | 5720 | 0.570 |
Why?
|
Genetic Variation | 8 | 2021 | 220 | 0.570 |
Why?
|
Heart Diseases | 4 | 2022 | 276 | 0.570 |
Why?
|
Aged | 32 | 2020 | 14842 | 0.560 |
Why?
|
Heart-Assist Devices | 7 | 2020 | 221 | 0.550 |
Why?
|
NAV1.8 Voltage-Gated Sodium Channel | 1 | 2016 | 1 | 0.540 |
Why?
|
Desmoglein 2 | 6 | 2016 | 7 | 0.540 |
Why?
|
Transforming Growth Factor beta | 9 | 2013 | 384 | 0.510 |
Why?
|
Loeys-Dietz Syndrome | 2 | 2013 | 10 | 0.510 |
Why?
|
Diltiazem | 1 | 2014 | 25 | 0.500 |
Why?
|
Atrial Fibrillation | 3 | 2013 | 248 | 0.490 |
Why?
|
Registries | 12 | 2021 | 730 | 0.470 |
Why?
|
Genomics | 3 | 2018 | 168 | 0.450 |
Why?
|
Gene Frequency | 5 | 2021 | 207 | 0.450 |
Why?
|
Animals | 29 | 2022 | 20880 | 0.440 |
Why?
|
Follow-Up Studies | 22 | 2020 | 3256 | 0.440 |
Why?
|
Biopsy | 9 | 2020 | 539 | 0.440 |
Why?
|
Disease Progression | 11 | 2020 | 1037 | 0.440 |
Why?
|
Heart Transplantation | 7 | 2020 | 328 | 0.440 |
Why?
|
Aortic Aneurysm | 5 | 2013 | 77 | 0.440 |
Why?
|
Adolescent | 24 | 2021 | 8904 | 0.430 |
Why?
|
Stroke Volume | 6 | 2022 | 586 | 0.430 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2012 | 15 | 0.430 |
Why?
|
Ion Channels | 1 | 2012 | 72 | 0.410 |
Why?
|
Desmoplakins | 6 | 2020 | 14 | 0.410 |
Why?
|
Penetrance | 3 | 2013 | 17 | 0.410 |
Why?
|
Heart Ventricles | 8 | 2020 | 738 | 0.410 |
Why?
|
Retrospective Studies | 24 | 2022 | 7268 | 0.400 |
Why?
|
Ventricular Fibrillation | 3 | 2018 | 85 | 0.400 |
Why?
|
Heart Conduction System | 5 | 2017 | 119 | 0.400 |
Why?
|
Ventricular Function, Right | 3 | 2020 | 103 | 0.390 |
Why?
|
Consensus | 4 | 2019 | 211 | 0.380 |
Why?
|
United States | 19 | 2022 | 7338 | 0.380 |
Why?
|
Cause of Death | 4 | 2020 | 241 | 0.380 |
Why?
|
Filamins | 2 | 2021 | 17 | 0.380 |
Why?
|
Exercise | 4 | 2022 | 658 | 0.380 |
Why?
|
Exercise Tolerance | 3 | 2020 | 75 | 0.370 |
Why?
|
Disease Models, Animal | 14 | 2019 | 2550 | 0.370 |
Why?
|
Family | 6 | 2020 | 293 | 0.370 |
Why?
|
Polymorphism, Genetic | 2 | 2015 | 301 | 0.360 |
Why?
|
Ventricular Function, Left | 5 | 2022 | 481 | 0.360 |
Why?
|
Fibrillins | 10 | 2013 | 24 | 0.360 |
Why?
|
Fibrillin-1 | 10 | 2013 | 18 | 0.360 |
Why?
|
Proteins | 1 | 2014 | 473 | 0.360 |
Why?
|
Aged, 80 and over | 10 | 2020 | 4843 | 0.360 |
Why?
|
Myocarditis | 3 | 2019 | 49 | 0.360 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 700 | 0.350 |
Why?
|
Genotype | 12 | 2021 | 785 | 0.350 |
Why?
|
Ventricular Dysfunction, Left | 7 | 2022 | 277 | 0.340 |
Why?
|
Mice | 19 | 2022 | 8474 | 0.340 |
Why?
|
Cadherins | 2 | 2021 | 93 | 0.320 |
Why?
|
Echocardiography | 9 | 2021 | 515 | 0.310 |
Why?
|
Molecular Sequence Data | 5 | 2014 | 1446 | 0.300 |
Why?
|
gamma Catenin | 6 | 2016 | 11 | 0.290 |
Why?
|
Natriuretic Peptide, Brain | 2 | 2022 | 101 | 0.290 |
Why?
|
RNA Splice Sites | 1 | 2006 | 13 | 0.290 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2008 | 189 | 0.280 |
Why?
|
Heart | 1 | 2011 | 850 | 0.280 |
Why?
|
Desmocollins | 5 | 2020 | 6 | 0.280 |
Why?
|
Catheter Ablation | 4 | 2014 | 229 | 0.280 |
Why?
|
Exercise Test | 3 | 2020 | 242 | 0.280 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2019 | 185 | 0.270 |
Why?
|
Cardiac Resynchronization Therapy | 2 | 2022 | 119 | 0.260 |
Why?
|
Predictive Value of Tests | 10 | 2020 | 1465 | 0.260 |
Why?
|
Cardiomegaly | 1 | 2006 | 213 | 0.250 |
Why?
|
Treatment Outcome | 14 | 2022 | 7028 | 0.250 |
Why?
|
Interferon-alpha | 1 | 2005 | 46 | 0.250 |
Why?
|
Glucagonoma | 1 | 2004 | 3 | 0.250 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 5 | 2020 | 201 | 0.240 |
Why?
|
Baltimore | 6 | 2016 | 34 | 0.240 |
Why?
|
Prevalence | 7 | 2022 | 1609 | 0.240 |
Why?
|
Primary Prevention | 2 | 2018 | 115 | 0.240 |
Why?
|
Europe | 3 | 2020 | 196 | 0.230 |
Why?
|
Child, Preschool | 10 | 2015 | 3187 | 0.230 |
Why?
|
Incidence | 9 | 2020 | 1582 | 0.230 |
Why?
|
DNA | 4 | 2014 | 597 | 0.230 |
Why?
|
Child | 13 | 2019 | 6401 | 0.230 |
Why?
|
Time Factors | 8 | 2020 | 4655 | 0.230 |
Why?
|
Losartan | 5 | 2013 | 45 | 0.230 |
Why?
|
Angiotensin Receptor Antagonists | 3 | 2022 | 155 | 0.230 |
Why?
|
Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 2 | 0.220 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 58 | 0.210 |
Why?
|
Troponin I | 2 | 2016 | 34 | 0.210 |
Why?
|
Genetic Association Studies | 3 | 2021 | 103 | 0.210 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 84 | 0.210 |
Why?
|
Microsatellite Repeats | 2 | 2003 | 40 | 0.210 |
Why?
|
Netherlands | 3 | 2017 | 68 | 0.210 |
Why?
|
Amino Acid Sequence | 4 | 2009 | 1082 | 0.210 |
Why?
|
Skin | 3 | 2017 | 451 | 0.200 |
Why?
|
Maryland | 3 | 2016 | 77 | 0.200 |
Why?
|
Longitudinal Studies | 4 | 2017 | 1054 | 0.200 |
Why?
|
Genetics, Medical | 2 | 2018 | 17 | 0.200 |
Why?
|
Case-Control Studies | 5 | 2017 | 1549 | 0.200 |
Why?
|
Receptor, Angiotensin, Type 2 | 2 | 2011 | 31 | 0.200 |
Why?
|
Muscle Contraction | 2 | 2021 | 210 | 0.200 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 4 | 2013 | 95 | 0.200 |
Why?
|
Electric Countershock | 3 | 2017 | 130 | 0.200 |
Why?
|
Anti-Arrhythmia Agents | 2 | 2019 | 97 | 0.190 |
Why?
|
Apoptosis Inducing Factor | 1 | 2021 | 10 | 0.190 |
Why?
|
Age of Onset | 5 | 2015 | 188 | 0.190 |
Why?
|
Sequence Analysis, DNA | 3 | 2020 | 208 | 0.190 |
Why?
|
Expert Testimony | 1 | 2021 | 47 | 0.190 |
Why?
|
Rare Diseases | 1 | 2021 | 41 | 0.190 |
Why?
|
Amino Acid Substitution | 2 | 2017 | 137 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 2222 | 0.190 |
Why?
|
Alleles | 4 | 2021 | 386 | 0.190 |
Why?
|
Receptors, Transforming Growth Factor beta | 3 | 2013 | 56 | 0.190 |
Why?
|
Pancreatic Neoplasms | 1 | 2004 | 332 | 0.190 |
Why?
|
Vascular Remodeling | 1 | 2021 | 34 | 0.190 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2011 | 150 | 0.180 |
Why?
|
Ehlers-Danlos Syndrome | 1 | 2020 | 13 | 0.180 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 11 | 0.180 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2011 | 147 | 0.180 |
Why?
|
Diuretics | 1 | 2020 | 96 | 0.180 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 91 | 0.180 |
Why?
|
Diagnosis, Differential | 6 | 2020 | 1140 | 0.180 |
Why?
|
Double-Blind Method | 3 | 2019 | 1738 | 0.180 |
Why?
|
Drug Discovery | 1 | 2021 | 94 | 0.180 |
Why?
|
Calpain | 1 | 2021 | 205 | 0.170 |
Why?
|
Pregnancy | 5 | 2021 | 2334 | 0.170 |
Why?
|
Ankyrins | 1 | 2019 | 1 | 0.170 |
Why?
|
Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2019 | 9 | 0.170 |
Why?
|
Canada | 1 | 2020 | 266 | 0.170 |
Why?
|
Electrocardiography, Ambulatory | 3 | 2013 | 34 | 0.170 |
Why?
|
Joint Instability | 1 | 2020 | 87 | 0.170 |
Why?
|
Neutralization Tests | 2 | 2017 | 19 | 0.170 |
Why?
|
Evolution, Molecular | 1 | 2019 | 79 | 0.170 |
Why?
|
Cardiomyopathy, Restrictive | 2 | 2009 | 6 | 0.170 |
Why?
|
Wnt Signaling Pathway | 1 | 2019 | 57 | 0.160 |
Why?
|
Oxygen Consumption | 1 | 2020 | 258 | 0.160 |
Why?
|
Survival Analysis | 5 | 2018 | 714 | 0.160 |
Why?
|
Plectin | 1 | 2018 | 1 | 0.160 |
Why?
|
Induced Pluripotent Stem Cells | 2 | 2017 | 86 | 0.160 |
Why?
|
Statistics as Topic | 2 | 2016 | 219 | 0.160 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 39 | 0.160 |
Why?
|
Autopsy | 1 | 2018 | 56 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 929 | 0.160 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 438 | 0.160 |
Why?
|
Aorta | 5 | 2013 | 316 | 0.160 |
Why?
|
Quality of Life | 4 | 2021 | 1515 | 0.150 |
Why?
|
Sweden | 1 | 2017 | 21 | 0.150 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2006 | 230 | 0.150 |
Why?
|
Neuromuscular Diseases | 1 | 2017 | 14 | 0.150 |
Why?
|
Signal Transduction | 6 | 2013 | 2689 | 0.150 |
Why?
|
Ventricular Flutter | 1 | 2017 | 1 | 0.150 |
Why?
|
RNA, Transfer, Leu | 1 | 2017 | 5 | 0.150 |
Why?
|
Sweat Glands | 1 | 2017 | 10 | 0.150 |
Why?
|
Genes, Mitochondrial | 1 | 2017 | 4 | 0.150 |
Why?
|
Sensitivity and Specificity | 6 | 2017 | 1753 | 0.150 |
Why?
|
Syndrome | 4 | 2013 | 255 | 0.150 |
Why?
|
Leukoencephalopathies | 1 | 2017 | 13 | 0.150 |
Why?
|
Infant | 7 | 2022 | 2891 | 0.150 |
Why?
|
Creatinine | 2 | 2015 | 243 | 0.150 |
Why?
|
Muscular Diseases | 1 | 2017 | 41 | 0.150 |
Why?
|
Heart Block | 2 | 2009 | 49 | 0.150 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2017 | 83 | 0.150 |
Why?
|
Antineoplastic Agents | 1 | 2005 | 1070 | 0.150 |
Why?
|
Multilevel Analysis | 1 | 2017 | 7 | 0.150 |
Why?
|
Nerve Fibers | 1 | 2017 | 77 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 536 | 0.150 |
Why?
|
Prospective Studies | 8 | 2020 | 3703 | 0.140 |
Why?
|
RNA-Binding Proteins | 1 | 2019 | 215 | 0.140 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 47 | 0.140 |
Why?
|
Immunohistochemistry | 3 | 2016 | 1174 | 0.140 |
Why?
|
Cohort Studies | 5 | 2018 | 2356 | 0.140 |
Why?
|
CRISPR-Cas Systems | 1 | 2017 | 41 | 0.140 |
Why?
|
Arteriovenous Malformations | 1 | 2016 | 34 | 0.140 |
Why?
|
Recovery of Function | 1 | 2020 | 506 | 0.140 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 58 | 0.140 |
Why?
|
Thrombocytopenia | 1 | 2017 | 122 | 0.140 |
Why?
|
MAP Kinase Signaling System | 3 | 2015 | 247 | 0.140 |
Why?
|
Membrane Potentials | 1 | 2017 | 200 | 0.140 |
Why?
|
Pluripotent Stem Cells | 1 | 2017 | 42 | 0.140 |
Why?
|
Gene Editing | 1 | 2017 | 33 | 0.140 |
Why?
|
Heparin | 1 | 2017 | 205 | 0.140 |
Why?
|
Sodium | 1 | 2017 | 161 | 0.140 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 772 | 0.140 |
Why?
|
Live Birth | 1 | 2015 | 8 | 0.140 |
Why?
|
Antigens, CD | 1 | 2017 | 230 | 0.130 |
Why?
|
Cells, Cultured | 4 | 2016 | 2673 | 0.130 |
Why?
|
Mouth Mucosa | 1 | 2016 | 51 | 0.130 |
Why?
|
HEK293 Cells | 1 | 2017 | 326 | 0.130 |
Why?
|
Models, Statistical | 1 | 2019 | 448 | 0.130 |
Why?
|
Genetic Markers | 1 | 2016 | 144 | 0.130 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 240 | 0.130 |
Why?
|
Angiotensin II | 2 | 2013 | 220 | 0.130 |
Why?
|
Societies, Medical | 1 | 2018 | 403 | 0.130 |
Why?
|
Physical Endurance | 1 | 2015 | 38 | 0.130 |
Why?
|
Desmogleins | 1 | 2015 | 4 | 0.130 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2015 | 30 | 0.130 |
Why?
|
Cytokines | 1 | 2019 | 866 | 0.130 |
Why?
|
Survival Rate | 5 | 2017 | 1055 | 0.130 |
Why?
|
Transfection | 1 | 2017 | 782 | 0.120 |
Why?
|
Gene-Environment Interaction | 1 | 2014 | 31 | 0.120 |
Why?
|
Base Sequence | 2 | 2006 | 1015 | 0.120 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2016 | 117 | 0.120 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2006 | 174 | 0.120 |
Why?
|
Sulfones | 1 | 2014 | 45 | 0.120 |
Why?
|
Severity of Illness Index | 5 | 2017 | 1851 | 0.120 |
Why?
|
Pericardium | 1 | 2014 | 97 | 0.120 |
Why?
|
Brugada Syndrome | 1 | 2013 | 5 | 0.120 |
Why?
|
Age Factors | 3 | 2022 | 1860 | 0.120 |
Why?
|
Sodium Channels | 1 | 2013 | 24 | 0.120 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 546 | 0.120 |
Why?
|
Cardiology | 1 | 2015 | 140 | 0.120 |
Why?
|
Zebrafish Proteins | 1 | 2014 | 100 | 0.110 |
Why?
|
TRPP Cation Channels | 1 | 2013 | 20 | 0.110 |
Why?
|
Hemodynamics | 2 | 2016 | 705 | 0.110 |
Why?
|
Mice, Inbred C57BL | 6 | 2021 | 2791 | 0.110 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2013 | 25 | 0.110 |
Why?
|
Vasodilator Agents | 1 | 2014 | 138 | 0.110 |
Why?
|
Progeria | 1 | 2013 | 6 | 0.110 |
Why?
|
Sarcoidosis | 1 | 2014 | 77 | 0.110 |
Why?
|
Epithelial Cells | 1 | 2016 | 431 | 0.110 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 157 | 0.110 |
Why?
|
Hospitalization | 4 | 2021 | 977 | 0.110 |
Why?
|
Inflammation | 1 | 2019 | 1030 | 0.110 |
Why?
|
Electrophysiologic Techniques, Cardiac | 4 | 2017 | 61 | 0.110 |
Why?
|
Vascular Diseases | 1 | 2013 | 94 | 0.110 |
Why?
|
Postmortem Changes | 1 | 2012 | 15 | 0.110 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2012 | 5 | 0.110 |
Why?
|
Amyloidogenic Proteins | 1 | 2012 | 4 | 0.110 |
Why?
|
Early Diagnosis | 3 | 2022 | 122 | 0.110 |
Why?
|
Giant Cells | 2 | 2016 | 14 | 0.110 |
Why?
|
Piperazines | 1 | 2014 | 206 | 0.110 |
Why?
|
Cell Cycle | 1 | 2014 | 312 | 0.110 |
Why?
|
Cardiovascular Diseases | 2 | 2017 | 938 | 0.110 |
Why?
|
Mice, Transgenic | 2 | 2013 | 1033 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 710 | 0.100 |
Why?
|
Calcium-Binding Proteins | 1 | 2012 | 114 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 230 | 0.100 |
Why?
|
Algorithms | 1 | 2018 | 1195 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.090 |
Why?
|
Aging | 2 | 2017 | 911 | 0.090 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2012 | 214 | 0.090 |
Why?
|
Elastic Tissue | 2 | 2007 | 28 | 0.090 |
Why?
|
Infant, Newborn | 4 | 2019 | 2455 | 0.090 |
Why?
|
Carrier Proteins | 2 | 2012 | 597 | 0.090 |
Why?
|
Nuclear Proteins | 1 | 2012 | 271 | 0.090 |
Why?
|
Myocardial Contraction | 3 | 2020 | 383 | 0.090 |
Why?
|
Troponin T | 1 | 2009 | 16 | 0.090 |
Why?
|
Preconception Care | 1 | 2009 | 14 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 2265 | 0.090 |
Why?
|
Sex Factors | 2 | 2020 | 1265 | 0.090 |
Why?
|
Artifacts | 1 | 2010 | 125 | 0.090 |
Why?
|
Transcription Factors | 1 | 2014 | 753 | 0.090 |
Why?
|
Cardiovascular Agents | 2 | 2008 | 82 | 0.090 |
Why?
|
North America | 1 | 2009 | 111 | 0.080 |
Why?
|
Sequence Alignment | 1 | 2009 | 165 | 0.080 |
Why?
|
Mice, Knockout | 4 | 2019 | 1692 | 0.080 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 951 | 0.080 |
Why?
|
Heredity | 1 | 2008 | 9 | 0.080 |
Why?
|
Inheritance Patterns | 1 | 2008 | 7 | 0.080 |
Why?
|
Cicatrix | 2 | 2022 | 60 | 0.080 |
Why?
|
Recurrence | 3 | 2020 | 948 | 0.080 |
Why?
|
Cardiac Myosins | 1 | 2008 | 12 | 0.080 |
Why?
|
Endocarditis | 1 | 2008 | 14 | 0.080 |
Why?
|
Biomarkers | 4 | 2017 | 1593 | 0.080 |
Why?
|
Surveys and Questionnaires | 1 | 2016 | 2798 | 0.080 |
Why?
|
Fat Necrosis | 1 | 2007 | 2 | 0.080 |
Why?
|
Myosin Heavy Chains | 1 | 2008 | 49 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2022 | 242 | 0.080 |
Why?
|
Vasculitis | 1 | 2007 | 33 | 0.080 |
Why?
|
Candida glabrata | 1 | 2007 | 3 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2015 | 848 | 0.070 |
Why?
|
Candidiasis | 1 | 2007 | 39 | 0.070 |
Why?
|
RNA Splicing | 1 | 2006 | 32 | 0.070 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2022 | 140 | 0.070 |
Why?
|
Indoles | 2 | 2019 | 146 | 0.070 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2007 | 145 | 0.070 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2007 | 160 | 0.070 |
Why?
|
Scleroderma, Systemic | 1 | 2010 | 446 | 0.070 |
Why?
|
Graft Rejection | 1 | 2009 | 458 | 0.070 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2007 | 134 | 0.070 |
Why?
|
DNA Primers | 1 | 2006 | 302 | 0.070 |
Why?
|
American Heart Association | 2 | 2017 | 142 | 0.070 |
Why?
|
Boston | 2 | 2016 | 35 | 0.070 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2007 | 317 | 0.060 |
Why?
|
Activin Receptors, Type I | 1 | 2005 | 14 | 0.060 |
Why?
|
Bone Development | 1 | 2005 | 37 | 0.060 |
Why?
|
Mass Spectrometry | 2 | 2018 | 284 | 0.060 |
Why?
|
Skull | 1 | 2005 | 63 | 0.060 |
Why?
|
Face | 1 | 2005 | 46 | 0.060 |
Why?
|
Tachycardia, Sinus | 1 | 2004 | 4 | 0.060 |
Why?
|
Mitral Valve Prolapse | 1 | 2004 | 40 | 0.060 |
Why?
|
Cardiac Catheterization | 2 | 2020 | 419 | 0.060 |
Why?
|
Immunoglobulin lambda-Chains | 2 | 2015 | 10 | 0.060 |
Why?
|
Cardiovascular System | 1 | 2005 | 85 | 0.060 |
Why?
|
Mice, 129 Strain | 2 | 2013 | 44 | 0.060 |
Why?
|
Haploinsufficiency | 2 | 2013 | 14 | 0.060 |
Why?
|
Mice, Mutant Strains | 2 | 2013 | 166 | 0.060 |
Why?
|
Lymphatic Metastasis | 1 | 2004 | 274 | 0.060 |
Why?
|
Patient Selection | 2 | 2017 | 592 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 791 | 0.060 |
Why?
|
Recombinant Proteins | 1 | 2005 | 742 | 0.050 |
Why?
|
PPAR alpha | 1 | 2022 | 31 | 0.050 |
Why?
|
Smad2 Protein | 2 | 2013 | 42 | 0.050 |
Why?
|
Trust | 1 | 2023 | 75 | 0.050 |
Why?
|
Ultrasonography | 1 | 2004 | 453 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2005 | 342 | 0.050 |
Why?
|
Fibrosis | 2 | 2015 | 371 | 0.050 |
Why?
|
Informed Consent | 1 | 2023 | 127 | 0.050 |
Why?
|
Receptor, Angiotensin, Type 1 | 2 | 2015 | 80 | 0.050 |
Why?
|
Diuresis | 1 | 2020 | 20 | 0.050 |
Why?
|
Melanoma | 1 | 2005 | 335 | 0.050 |
Why?
|
Protein Domains | 1 | 2021 | 74 | 0.050 |
Why?
|
Point Mutation | 1 | 2001 | 97 | 0.050 |
Why?
|
Risk | 1 | 2022 | 563 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2005 | 375 | 0.050 |
Why?
|
Elastin | 2 | 2012 | 116 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 68 | 0.050 |
Why?
|
Global Health | 1 | 2020 | 135 | 0.050 |
Why?
|
Cell Death | 1 | 2021 | 329 | 0.040 |
Why?
|
Mole Rats | 1 | 2019 | 8 | 0.040 |
Why?
|
Loss of Function Mutation | 1 | 2019 | 12 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 149 | 0.040 |
Why?
|
Polyploidy | 1 | 2019 | 24 | 0.040 |
Why?
|
Rats, Transgenic | 1 | 2019 | 24 | 0.040 |
Why?
|
Disease Management | 1 | 2021 | 248 | 0.040 |
Why?
|
Maleimides | 1 | 2019 | 15 | 0.040 |
Why?
|
Genes, Dominant | 2 | 2013 | 51 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2005 | 561 | 0.040 |
Why?
|
beta Catenin | 1 | 2019 | 73 | 0.040 |
Why?
|
Cell Lineage | 1 | 2019 | 146 | 0.040 |
Why?
|
Regeneration | 1 | 2019 | 105 | 0.040 |
Why?
|
Walk Test | 1 | 2018 | 10 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2003 | 617 | 0.040 |
Why?
|
Genetics | 1 | 2018 | 6 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
Tissue Donors | 1 | 2020 | 195 | 0.040 |
Why?
|
Rats, Wistar | 1 | 2019 | 371 | 0.040 |
Why?
|
Incidental Findings | 1 | 2018 | 42 | 0.040 |
Why?
|
Heart Rate | 2 | 2012 | 568 | 0.040 |
Why?
|
Extracellular Matrix | 2 | 2012 | 493 | 0.040 |
Why?
|
Myopathies, Structural, Congenital | 1 | 2017 | 2 | 0.040 |
Why?
|
Friedreich Ataxia | 1 | 2017 | 6 | 0.040 |
Why?
|
Health Care Costs | 1 | 2020 | 346 | 0.040 |
Why?
|
Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 2 | 0.040 |
Why?
|
Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 2 | 0.040 |
Why?
|
Barth Syndrome | 1 | 2017 | 5 | 0.040 |
Why?
|
Platelet Factor 4 | 1 | 2017 | 10 | 0.040 |
Why?
|
Logistic Models | 2 | 2016 | 1419 | 0.040 |
Why?
|
Genome, Human | 1 | 2017 | 62 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 170 | 0.040 |
Why?
|
Acute Disease | 1 | 2019 | 658 | 0.040 |
Why?
|
Professional-Family Relations | 1 | 2017 | 45 | 0.040 |
Why?
|
Myotonic Dystrophy | 1 | 2017 | 19 | 0.040 |
Why?
|
Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
Diabetic Neuropathies | 1 | 2017 | 33 | 0.040 |
Why?
|
Mouse Embryonic Stem Cells | 1 | 2017 | 4 | 0.040 |
Why?
|
Cell Shape | 1 | 2017 | 37 | 0.040 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 34 | 0.040 |
Why?
|
Coronary Artery Disease | 1 | 2003 | 696 | 0.040 |
Why?
|
Single-Cell Analysis | 1 | 2017 | 35 | 0.040 |
Why?
|
Greece | 1 | 2016 | 3 | 0.030 |
Why?
|
Clinical Decision-Making | 1 | 2017 | 109 | 0.030 |
Why?
|
Mitochondria | 1 | 2021 | 643 | 0.030 |
Why?
|
Hydralazine | 1 | 2015 | 12 | 0.030 |
Why?
|
Protein Kinase C beta | 1 | 2015 | 19 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2017 | 396 | 0.030 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2015 | 11 | 0.030 |
Why?
|
Cesarean Section | 1 | 2015 | 101 | 0.030 |
Why?
|
Connexin 43 | 1 | 2016 | 62 | 0.030 |
Why?
|
Protein Structure, Quaternary | 1 | 2015 | 31 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2019 | 718 | 0.030 |
Why?
|
Respiration Disorders | 1 | 2015 | 20 | 0.030 |
Why?
|
Physical Exertion | 1 | 2015 | 75 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2015 | 63 | 0.030 |
Why?
|
Desmoglein 3 | 1 | 2015 | 2 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2015 | 106 | 0.030 |
Why?
|
Serum Amyloid A Protein | 1 | 2015 | 33 | 0.030 |
Why?
|
Child Development | 1 | 2015 | 102 | 0.030 |
Why?
|
Epicardial Mapping | 1 | 2014 | 4 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2019 | 1174 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2015 | 38 | 0.030 |
Why?
|
Protein Folding | 1 | 2015 | 82 | 0.030 |
Why?
|
Protein Stability | 1 | 2015 | 89 | 0.030 |
Why?
|
Communication | 1 | 2017 | 329 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2015 | 86 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 711 | 0.030 |
Why?
|
Age Distribution | 1 | 2015 | 319 | 0.030 |
Why?
|
Dystrophin | 1 | 2014 | 6 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2015 | 71 | 0.030 |
Why?
|
Homeobox Protein Nkx-2.5 | 1 | 2014 | 27 | 0.030 |
Why?
|
Muscle Cells | 1 | 2014 | 30 | 0.030 |
Why?
|
Sildenafil Citrate | 1 | 2014 | 23 | 0.030 |
Why?
|
Purines | 1 | 2014 | 39 | 0.030 |
Why?
|
Cardiac Output | 1 | 2014 | 133 | 0.030 |
Why?
|
Electrophysiology | 1 | 2014 | 160 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2015 | 190 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2019 | 807 | 0.030 |
Why?
|
Fibroblasts | 2 | 2013 | 902 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2014 | 349 | 0.030 |
Why?
|
Simethicone | 1 | 2013 | 1 | 0.030 |
Why?
|
Cetrimonium Compounds | 1 | 2013 | 4 | 0.030 |
Why?
|
Nicotinic Acids | 1 | 2013 | 5 | 0.030 |
Why?
|
Stearic Acids | 1 | 2013 | 6 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 567 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2014 | 249 | 0.030 |
Why?
|
Myristates | 1 | 2013 | 21 | 0.030 |
Why?
|
Epistasis, Genetic | 1 | 2013 | 32 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2014 | 392 | 0.030 |
Why?
|
Protein Modification, Translational | 1 | 2013 | 1 | 0.030 |
Why?
|
Farnesyltranstransferase | 1 | 2013 | 5 | 0.030 |
Why?
|
Nuclear Envelope | 1 | 2013 | 8 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2015 | 222 | 0.030 |
Why?
|
Patch-Clamp Techniques | 1 | 2013 | 204 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 65 | 0.030 |
Why?
|
Zebrafish | 1 | 2014 | 187 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 160 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 492 | 0.030 |
Why?
|
Laser Capture Microdissection | 1 | 2012 | 3 | 0.030 |
Why?
|
Coronary Vessels | 2 | 2007 | 313 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2014 | 181 | 0.030 |
Why?
|
Calcium | 1 | 2017 | 929 | 0.030 |
Why?
|
Immunoassay | 1 | 2012 | 64 | 0.030 |
Why?
|
Dopamine | 1 | 2015 | 474 | 0.030 |
Why?
|
Drug Combinations | 1 | 2013 | 304 | 0.030 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2013 | 144 | 0.030 |
Why?
|
Tensile Strength | 1 | 2012 | 90 | 0.030 |
Why?
|
Mass Screening | 1 | 2018 | 838 | 0.030 |
Why?
|
Electrophoresis | 1 | 2012 | 69 | 0.030 |
Why?
|
Morbidity | 1 | 2012 | 130 | 0.030 |
Why?
|
Action Potentials | 1 | 2013 | 223 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2012 | 61 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2012 | 337 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 497 | 0.020 |
Why?
|
Diphenylamine | 1 | 2011 | 3 | 0.020 |
Why?
|
Mortality | 1 | 2012 | 162 | 0.020 |
Why?
|
Smad4 Protein | 1 | 2011 | 10 | 0.020 |
Why?
|
Anthracenes | 1 | 2011 | 26 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 17 | 0.020 |
Why?
|
Biomechanical Phenomena | 1 | 2012 | 368 | 0.020 |
Why?
|
Aortic Rupture | 1 | 2011 | 32 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 1293 | 0.020 |
Why?
|
Atherosclerosis | 1 | 2013 | 204 | 0.020 |
Why?
|
Enalapril | 1 | 2011 | 86 | 0.020 |
Why?
|
Chronic Disease | 2 | 2006 | 1329 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 507 | 0.020 |
Why?
|
Proteomics | 1 | 2012 | 246 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2010 | 121 | 0.020 |
Why?
|
Microfibrils | 1 | 2010 | 2 | 0.020 |
Why?
|
Sulfonamides | 1 | 2011 | 141 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 659 | 0.020 |
Why?
|
Observer Variation | 1 | 2010 | 330 | 0.020 |
Why?
|
Cell Line | 1 | 2013 | 1752 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 791 | 0.020 |
Why?
|
Body Surface Potential Mapping | 1 | 2009 | 10 | 0.020 |
Why?
|
Mesoderm | 1 | 2010 | 231 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2010 | 324 | 0.020 |
Why?
|
Contrast Media | 1 | 2012 | 595 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2011 | 331 | 0.020 |
Why?
|
Anthracyclines | 1 | 2007 | 9 | 0.020 |
Why?
|
Biphenyl Compounds | 1 | 2008 | 184 | 0.020 |
Why?
|
Tetrazoles | 1 | 2008 | 160 | 0.020 |
Why?
|
Time | 1 | 2007 | 57 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2007 | 164 | 0.020 |
Why?
|
Cell Movement | 1 | 2010 | 630 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2007 | 242 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2009 | 483 | 0.020 |
Why?
|
Collagen | 1 | 2010 | 636 | 0.020 |
Why?
|
Linear Models | 1 | 2008 | 521 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 648 | 0.020 |
Why?
|
Actins | 1 | 2007 | 249 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2006 | 62 | 0.020 |
Why?
|
Syncope | 1 | 2005 | 23 | 0.020 |
Why?
|
Propranolol | 1 | 2006 | 102 | 0.020 |
Why?
|
Equipment Failure | 1 | 2006 | 112 | 0.020 |
Why?
|
Aorta, Thoracic | 1 | 2007 | 211 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2006 | 100 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2010 | 2077 | 0.020 |
Why?
|
Antibodies | 1 | 2006 | 241 | 0.020 |
Why?
|
Pacemaker, Artificial | 1 | 2006 | 157 | 0.020 |
Why?
|
Fluoroscopy | 1 | 2006 | 152 | 0.020 |
Why?
|
Up-Regulation | 1 | 2007 | 682 | 0.020 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2004 | 43 | 0.020 |
Why?
|
Systole | 1 | 2004 | 149 | 0.020 |
Why?
|
Lung Diseases | 1 | 2006 | 175 | 0.010 |
Why?
|
Diastole | 1 | 2004 | 161 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 2324 | 0.010 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2003 | 9 | 0.010 |
Why?
|
Codon, Nonsense | 1 | 2003 | 15 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 1040 | 0.010 |
Why?
|
Thallium Radioisotopes | 1 | 2003 | 13 | 0.010 |
Why?
|
Glucuronidase | 1 | 2003 | 11 | 0.010 |
Why?
|
Haplotypes | 1 | 2003 | 174 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.010 |
Why?
|
Ventricular Remodeling | 1 | 2006 | 318 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2006 | 286 | 0.010 |
Why?
|
Siblings | 1 | 2003 | 34 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2003 | 166 | 0.010 |
Why?
|
Gene Deletion | 1 | 2003 | 235 | 0.010 |
Why?
|
Blood Pressure | 1 | 2008 | 1449 | 0.010 |
Why?
|
Neoplasms | 1 | 2013 | 1664 | 0.010 |
Why?
|
Lung | 1 | 2006 | 849 | 0.010 |
Why?
|
Gene Expression | 1 | 2003 | 770 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2003 | 1663 | 0.010 |
Why?
|